|1.||Brodie, Angela M H: 1 article (10/2004)|
|2.||Long, Brian J: 1 article (10/2004)|
|3.||Nnane, Ivo P: 1 article (10/2004)|
|4.||Jelovac, Danijela: 1 article (10/2004)|
|5.||Handratta, Venkatesh D: 1 article (10/2004)|
|6.||Njar, Vincent C O: 1 article (10/2004)|
|7.||Kataria, Ritesh: 1 article (10/2004)|
|1.||Prostatic Neoplasms (Prostate Cancer)
10/01/1999 - "These results suggest that VN/85-1 and VN/87-1 may be potential candidates for treatment of prostate cancer."
10/01/2004 - "These results indicate that VN/85-1 or VN/87-1 may be useful in the treatment of hormone-dependent prostate cancer."
10/01/1999 - "We designed and evaluated two groups of azolyl steroids: delta5-non-competitive inhibitors (delta5NCIs), VN/63-1, VN/85-1, VN/87-1 and their corresponding delta4 derivatives (delta4NCIs), VN/107-1, VN/108-1 and VN/109-1. The human P450c17 gene was transfected into LNCaP human prostate cancer cells, and the resultant LNCaP-CYP17 cells were utilized to evaluate the inhibitory potency of the new azolyl steroids. "
10/01/2004 - "However, at their effective dosage regimes, VN/85-1 and VN/87-1 were each as effective as castration and more effective than finasteride or casodex, an anti-androgen used for prostate cancer (PC) therapy. "
|1.||3- hydroxy- 17- (1H- 1,2,3- triazol- 1- yl)androsta- 5,16- diene